Proteins and pathways in atrial fibrillation and atrial cardiomyopathy underlying cryptogenic stroke.
Atrial cardiomyopathy
Atrial fibrillation
Atrial function
Biomarkers
Cryptogenic stroke
Journal
International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
14
01
2022
revised:
16
02
2022
accepted:
17
02
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Atrial fibrillation (AF) is one of the most prevalent causes of cryptogenic stroke. Also, apart from AF itself, structural and remodelling changes in the atria might be an underlying cause of cryptogenic stroke. We aimed to discover circulating proteins and reveal pathways altered in AF and atrial cardiomyopathy, measured by left atrial volume index (LAVI) and peak atrial longitudinal strain (PALS), in patients with cryptogenic stroke. An aptamer array (including 1310 proteins) was measured in the blood of 20 cryptogenic stroke patients monitored during 28 days with a Holter device as a case-control study of the Crypto-AF cohort. Protein levels were compared between patients with (n = 10) and without AF (n = 10) after stroke, and the best candidates were tested in 111 patients from the same cohort (44 patients with AF and 67 without AF). In addition, in the first 20 patients, proteins were explored according to PALS and LAVI values. Forty-six proteins were differentially expressed in AF cases. Of those, four proteins were tested in a larger sample size. Only DPP7, presenting lower levels in AF patients, was further validated. Fifty-seven proteins correlated with LAVI, and 270 correlated with PALS. NT-proBNP was common in all the discovery analyses performed. Interestingly, many proteins and pathways were altered in patients with low PALS. Multiple proteins and pathways related to AF and atrial cardiomyopathy have been revealed. The role of DPP7 as a biomarker for stroke aetiology should be further explored. Moreover, the present study may be considered hypothesis-generating.
Sections du résumé
Background
UNASSIGNED
Atrial fibrillation (AF) is one of the most prevalent causes of cryptogenic stroke. Also, apart from AF itself, structural and remodelling changes in the atria might be an underlying cause of cryptogenic stroke. We aimed to discover circulating proteins and reveal pathways altered in AF and atrial cardiomyopathy, measured by left atrial volume index (LAVI) and peak atrial longitudinal strain (PALS), in patients with cryptogenic stroke.
Methods
UNASSIGNED
An aptamer array (including 1310 proteins) was measured in the blood of 20 cryptogenic stroke patients monitored during 28 days with a Holter device as a case-control study of the Crypto-AF cohort. Protein levels were compared between patients with (n = 10) and without AF (n = 10) after stroke, and the best candidates were tested in 111 patients from the same cohort (44 patients with AF and 67 without AF). In addition, in the first 20 patients, proteins were explored according to PALS and LAVI values.
Results
UNASSIGNED
Forty-six proteins were differentially expressed in AF cases. Of those, four proteins were tested in a larger sample size. Only DPP7, presenting lower levels in AF patients, was further validated. Fifty-seven proteins correlated with LAVI, and 270 correlated with PALS. NT-proBNP was common in all the discovery analyses performed. Interestingly, many proteins and pathways were altered in patients with low PALS.
Conclusions
UNASSIGNED
Multiple proteins and pathways related to AF and atrial cardiomyopathy have been revealed. The role of DPP7 as a biomarker for stroke aetiology should be further explored. Moreover, the present study may be considered hypothesis-generating.
Identifiants
pubmed: 35281755
doi: 10.1016/j.ijcha.2022.100977
pii: S2352-9067(22)00026-4
pmc: PMC8913305
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100977Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Eur J Neurol. 2021 Feb;28(2):540-547
pubmed: 33043545
Int J Cardiol. 2021 Dec 1;344:205-212
pubmed: 34592249
Cardiovasc Diagn Ther. 2018 Feb;8(1):29-46
pubmed: 29541609
Stroke. 2014 Aug;45(8):e164-6
pubmed: 24968931
Circulation. 2015 Jul 28;132(4):278-91
pubmed: 26216085
Front Immunol. 2015 Aug 07;6:387
pubmed: 26300881
Nat Rev Dis Primers. 2016 Mar 31;2:16016
pubmed: 27159789
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Nat Rev Cardiol. 2015 Apr;12(4):230-43
pubmed: 25622848
JACC Clin Electrophysiol. 2017 May;3(5):425-435
pubmed: 29759598
Int J Stroke. 2019 Feb;14(2):207-214
pubmed: 30196789
Curr Cardiol Rep. 2018 Sep 12;20(11):103
pubmed: 30209635
Cerebrovasc Dis Extra. 2020;10(1):11-20
pubmed: 32028277
Proteomics. 2020 Jun;20(12):e1900278
pubmed: 32386347
Int J Cardiol. 2018 Jan 15;251:45-50
pubmed: 29107360
Clin Chim Acta. 2007 May 1;380(1-2):31-49
pubmed: 17328877
Front Neurol. 2021 Feb 25;12:624930
pubmed: 33716927
Lancet. 2016 Aug 20;388(10046):806-17
pubmed: 27560276
Eur Heart J Cardiovasc Imaging. 2016 Apr;17(4):355-83
pubmed: 26864186
J Am Heart Assoc. 2019 Mar 19;8(6):e010976
pubmed: 30841775
Transl Stroke Res. 2021 Oct;12(5):735-741
pubmed: 33184686
J Am Soc Echocardiogr. 2017 Jan;30(1):59-70.e8
pubmed: 28341032
Front Pharmacol. 2020 Mar 04;11:129
pubmed: 32194399
PLoS One. 2010 Dec 07;5(12):e15004
pubmed: 21165148
N Engl J Med. 2014 Jun 26;370(26):2478-86
pubmed: 24963567
Nat Protoc. 2019 Feb;14(2):482-517
pubmed: 30664679
Sci Rep. 2017 Oct 27;7(1):14248
pubmed: 29079756
Stroke. 2019 Aug;50(8):1997-2001
pubmed: 31189435
Heart. 2017 Mar;103(5):377-382
pubmed: 27609943
Eur Heart J Suppl. 2020 Dec 06;22(Suppl M):M51-M59
pubmed: 33664640
Eur J Neurol. 2020 Aug;27(8):1618-1624
pubmed: 32347993
Circulation. 2019 Nov 26;140(22):1834-1850
pubmed: 31765261